Skip to main content
Year archive

BioLineRx Ltd. — 2020 filings

All 136 regulatory filings released by BioLineRx Ltd. (BLRX) in 2020, sourced directly from the official regulator.

136 Filings
2020 Period
2020 filings (136)
Filing Released Lang
F-3
Regulatory Filings
2020-12-31 English
424B5
Prospectus
2020-12-31 English
Presentation for KOL webinar to discuss final results from COMBAT / KEYNOTE-202 Phase 2a study in Metastatic Pancreatic Cancer
Investor Presentation
2020-12-16 English
Presentation for KOL webinar to discuss final results from COMBAT / KEYNOTE-202 Phase 2a study in Metastatic Pancreatic Cancer
Investor Presentation
2020-12-16 English
6-K
Foreign Filer Report
2020-12-16 English
Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
Regulatory Filings
2020-12-16 English
Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
Report Publication Announcement
2020-12-16 English
6-K
Foreign Filer Report
2020-12-16 English
Third Quarter 2020 Financial Results
Interim / Quarterly Report 9M 2020
2020-11-23 English
Third Quarter 2020 Financial Results
Report Publication Announcement Q3 2020
2020-11-23 English
6-K
Foreign Filer Report
2020-11-23 English
Initiation of Phase 1b Clinical Trial in Patients with Acute Respiratory Distress Syndrome (ARDS) Secondary to COVID-19 and Other Respiratory Viral Infections
Regulatory Filings
2020-11-18 English
Initiation of Phase 1b Clinical Trial in Patients with Acute Respiratory Distress Syndrome (ARDS) Secondary to COVID-19 and Other Respiratory Viral Infections
Report Publication Announcement
2020-11-18 English
6-K
Foreign Filer Report
2020-11-18 English
PROSPECTUS SUPPLEMENT-Up to $4,430,000 of American Depositary Shares Representing Ordinary Shares
Capital/Financing Update
2020-11-15 English
PROSPECTUS SUPPLEMENT-Up to $4,430,000 of American Depositary Shares Representing Ordinary Shares
Report Publication Announcement
2020-11-15 English
424B5
Prospectus
2020-11-13 English
AMENDMENT NO. 2 TO THE SCHEDULE 13G
Major Shareholding Notification
2020-11-03 English
Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization
Regulatory Filings
2020-10-30 English
Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization
Report Publication Announcement
2020-10-30 English
6-K
Foreign Filer Report
2020-10-30 English
BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer
Regulatory Filings
2020-10-29 English
BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer
Report Publication Announcement
2020-10-29 English
6-K
Foreign Filer Report
2020-10-29 English
PROSPECTUS SUPPLEMENT - ATM
Capital/Financing Update
2020-09-27 English
PROSPECTUS SUPPLEMENT - ATM
Report Publication Announcement
2020-09-27 English
enters into At-The-Market Agreement with H.C. Wainwright & Co., LLC
Regulatory Filings
2020-09-27 English
enters into At-The-Market Agreement with H.C. Wainwright & Co., LLC
Report Publication Announcement
2020-09-27 English
6-K
Foreign Filer Report
2020-09-25 English
424B5
Prospectus
2020-09-25 English
reports results of shareholders meeting
Declaration of Voting Results & Voting Rights Announcements
2020-09-25 English
reports results of shareholders meeting
AGM Information
2020-09-25 English
6-K
Foreign Filer Report
2020-09-24 English
ANNUAL GENERAL MEETING OF SHAREHOLDERS to be held ON SEPTEMBER 24, 2020
Proxy Solicitation & Information Statement
2020-08-20 English
ANNUAL GENERAL MEETING OF SHAREHOLDERS to be held ON SEPTEMBER 24, 2020
AGM Information
2020-08-20 English
ANNUAL GENERAL MEETING OF SHAREHOLDERS to be held ON SEPTEMBER 24, 2020
AGM Information
2020-08-20 English
6-K
Foreign Filer Report
2020-08-19 English
BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis
Regulatory Filings
2020-08-19 English
BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis
Report Publication Announcement
2020-08-19 English
6-K
Foreign Filer Report
2020-08-19 English
Regulatory Filings 2020
Regulatory Filings
2020-08-13 English
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1-REGISTRATION STATEMENT
Capital/Financing Update
2020-08-09 English
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1-REGISTRATION STATEMENT
Capital/Financing Update
2020-08-09 English
POS AM
Regulatory Filings
2020-08-07 English
BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Interim / Quarterly Report Q2 2020
2020-08-06 English
BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Report Publication Announcement Q2 2020
2020-08-06 English
The company's financial statements for the second quarter 2020 reported abroad
Regulatory Filings
2020-08-06 Hebrew (modern)
6-K
Foreign Filer Report
2020-08-06 English
Regulatory Filings 2020
Regulatory Filings
2020-07-06 English
prospectus dated July 2, 2020 relates to the resale of ADS
Capital/Financing Update
2020-07-05 English
prospectus dated July 2, 2020 relates to the resale of ADS
Report Publication Announcement
2020-07-05 English
424B3
Prospectus
2020-07-02 English
Regulatory Filings 2020
Regulatory Filings
2020-07-01 English
Regulatory Filings 2020
Regulatory Filings
2020-07-01 English
FORM F-1-REGISTRATION STATEMENT
Capital/Financing Update
2020-06-28 English
FORM F-1-REGISTRATION STATEMENT
Regulatory Filings
2020-06-28 English
F-1
Regulatory Filings
2020-06-26 English
FORM D Notice of Exempt Offering of Securities June 2020
Capital/Financing Update
2020-06-10 English
FORM D Notice of Exempt Offering of Securities June 2020
Report Publication Announcement
2020-06-10 English
FORM D Notice of Exempt Offering of Securities May 2020
Capital/Financing Update
2020-06-10 English
FORM D Notice of Exempt Offering of Securities May 2020
Report Publication Announcement
2020-06-10 English
Regulatory Filings 2020
Regulatory Filings
2020-06-10 English
Regulatory Filings 2020
Regulatory Filings
2020-06-10 English
Form 13-G filed by Intracoastal Capital LLC
Major Shareholding Notification
2020-06-09 English
Form 13-G filed by Intracoastal Capital LLC
Major Shareholding Notification
2020-06-09 English
SCHEDULE 13G
Major Shareholding Notification
2020-06-09 English
SCHEDULE 13G
Major Shareholding Notification
2020-06-09 English
Form 13G filed with the SEC by Altium Capital Management, LP
Major Shareholding Notification
2020-06-09 English
Form 13G filed with the SEC by Altium Capital Management, LP
Report Publication Announcement FY 2020
2020-06-09 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-06-05 English
SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP
Major Shareholding Notification
2020-06-05 English
SCHEDULE 13G
Major Shareholding Notification
2020-06-05 English
Prospectus supplement for offering
Capital/Financing Update
2020-06-03 English
Prospectus supplement for offering
Report Publication Announcement
2020-06-03 English
BioLine announces the closing of its previously announced $4.39 million registered
Regulatory Filings
2020-06-03 English
BioLine announces the closing of its previously announced $4.39 million registered
Report Publication Announcement FY 2020
2020-06-03 English
424B5
Prospectus
2020-06-03 English
6-K
Foreign Filer Report
2020-06-03 English
AMENDMENT NO. 1 TO THE SCHEDULE 13G
Major Shareholding Notification
2020-06-01 English
BioLineRx Announces $4.39 Million Registered Direct Offering
Capital/Financing Update
2020-06-01 English
BioLineRx Announces $4.39 Million Registered Direct Offering
Capital/Financing Update
2020-06-01 English
6-K
Foreign Filer Report
2020-06-01 English
Form 13-G filed by Sabby Volatility Warrant Master Fund, Ltd.
Major Shareholding Notification
2020-05-28 English
Form 13-G filed by Sabby Volatility Warrant Master Fund, Ltd.
Report Publication Announcement
2020-05-28 English
Prospectus supplement for offering
Capital/Financing Update
2020-05-28 English
Prospectus supplement for offering
Report Publication Announcement
2020-05-28 English
BioLine announces the closing of its previously announced $9.0 million registered direct offering
Regulatory Filings
2020-05-28 English
BioLine announces the closing of its previously announced $9.0 million registered direct offering
Capital/Financing Update
2020-05-28 English
424B5
Prospectus
2020-05-28 English
6-K
Foreign Filer Report
2020-05-28 English
BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial
Regulatory Filings
2020-05-27 English
BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial
Report Publication Announcement
2020-05-27 English
6-K
Foreign Filer Report
2020-05-27 English
SABBYY 13G BLRX 5.26.20
Major Shareholding Notification
2020-05-26 English
BioLineRx Announces $9.0 Million Registered Direct Offering
Capital/Financing Update
2020-05-26 English
BioLineRx Announces $9.0 Million Registered Direct Offering
Report Publication Announcement
2020-05-26 English
BioLine announces the termination of its prospectus supplement relating to ATM program with BTIG
Regulatory Filings
2020-05-26 English
BioLine announces the termination of its prospectus supplement relating to ATM program with BTIG
Report Publication Announcement
2020-05-26 English
6-K
Foreign Filer Report
2020-05-26 English
6-K
Foreign Filer Report
2020-05-26 English
Reports First Quarter 2020 Financial Results and Provides Corporate Update
Interim / Quarterly Report Q1 2020
2020-05-20 English
Reports First Quarter 2020 Financial Results and Provides Corporate Update
Report Publication Announcement Q1 2020
2020-05-20 English
6-K
Foreign Filer Report
2020-05-20 English
Prospectus Supplement related to previously announced At-the-Market Sales Agreement with BTIG, LLC
Capital/Financing Update
2020-04-19 English
Prospectus Supplement related to previously announced At-the-Market Sales Agreement with BTIG, LLC
Regulatory Filings
2020-04-19 English
424B5
Prospectus
2020-04-17 English
Regulatory Filings 2020
Regulatory Filings
2020-03-20 English
Annual Report on Form 20-F FOR 2019
Annual Report FY 2019
2020-03-12 English
Annual Report on Form 20-F FOR 2019
Report Publication Announcement
2020-03-12 English
BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update
Regulatory Filings
2020-03-12 English
BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update
Report Publication Announcement
2020-03-12 English
20-F
Annual Report FY 2019
2020-03-12 English
6-K
Foreign Filer Report
2020-03-12 English
6K: BioLineRx reports results of extraordinary meeting of shareholders
Declaration of Voting Results & Voting Rights Announcements
2020-03-05 English
6K: BioLineRx reports results of extraordinary meeting of shareholders
Report Publication Announcement
2020-03-05 English
6-K
Foreign Filer Report
2020-03-05 English
Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination with anti-PD-1 for the Treatment of any Type of Cancer
Regulatory Filings
2020-02-27 English
Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination with anti-PD-1 for the Treatment of any Type of Cancer
Report Publication Announcement
2020-02-27 English
6-K
Foreign Filer Report
2020-02-27 English
Regulatory Filings 2020
Regulatory Filings
2020-02-19 English
Form 13G filed with the SEC by BVF group
Major Shareholding Notification
2020-02-16 English
Form 13G filed with the SEC by BVF group
Regulatory Filings
2020-02-16 English
THE SCHEDULE 13G
Major Shareholding Notification
2020-02-14 English
Form 13G/A filed with the SEC by Senvest Management
Major Shareholding Notification
2020-02-10 English
Form 13G/A filed with the SEC by Senvest Management
Report Publication Announcement
2020-02-10 English
BIOLINERX LTD.
Major Shareholding Notification
2020-02-07 English
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ON MARCH 5, 20
Proxy Solicitation & Information Statement
2020-01-30 English
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ON MARCH 5, 20
AGM Information
2020-01-30 English
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ON MARCH 5, 20
Proxy Solicitation & Information Statement
2020-01-30 English
6-K
Foreign Filer Report
2020-01-30 English
BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients with Second-Line Metastatic Pancreatic Cancer
Regulatory Filings
2020-01-22 English
BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients with Second-Line Metastatic Pancreatic Cancer
Report Publication Announcement
2020-01-22 English
6-K
Foreign Filer Report
2020-01-22 English
BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe
Regulatory Filings
2020-01-14 English
BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe
Report Publication Announcement
2020-01-14 English
6-K
Foreign Filer Report
2020-01-14 English